In conclusion, this study indicated that low peripheral blood RRM1 was correlated with high chemotherapy efficacy and increased survival in NSCLC patients receiving gemcitabine and carboplatin combination therapy. The gene discussed is RRM1; the disease is non-small cell lung carcinoma.